November 15, 2012
When trial results come in for a company in the health care space, it's often do or die, make or break. In this video, Motley Fool health care analyst David Williamson takes us through three such results just in, and what's happened with shares as a result. Tranzyme (Nasdaq: TZYM ) was today's biggest loser, with shares down a devastating 75% after results came in that its drug TZP-102 was no better than a placebo in helping gastroparesis patients. AcelRX (Nasdaq: ACRX ) , on the other hand, was up after excellent results with its drug sufentanil nanotab pca in comparison with intravenous morphine for treating post-operative pain, and Threshold Pharmaceuticals (Nasdaq: THLD ) experienced a jump up that has now settled back down, after some initial excitement about the results of its drug TH302 applied to maintenance therapy for soft-tissue sarcoma.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.